Trity Environ Solutions manufactures sewage treatment plants for hospitals, built around what actually makes hospital wastewater different: pharmaceutical residues, disinfectant shock loads, and pathogen concentrations that standard biological treatment doesn't fully address. Our systems are CPCB compliant, engineered for pharmaceutical residues and pathogen removal, with hospital-grade AMC support built in.
Hospital wastewater carries active pharmaceutical ingredients, antibiotics, analgesics, hormones, and in oncology units, cytotoxic chemotherapy residues, that pass through patients metabolically and enter the drainage system. Standard biological treatment doesn't reliably break these compounds down, which means a conventional STP can pass every routine BOD and COD check while still discharging pharmaceutical residues the test wasn't designed to catch.
Antimicrobial resistance is a documented global health concern, and hospital wastewater is one pathway researchers study closely, though the picture is more nuanced than headlines suggest. A 2021 metagenomic study across four wastewater treatment plants in Jaipur actually found lower antibiotic resistance gene diversity in wastewater from a facility receiving only hospital effluent compared to plants handling mixed municipal sewage, a reminder that proper segregation and dedicated treatment design matter more than the source alone.
Planning or upgrading a hospital wastewater system? Request a free technical assessment and our engineering team will size the right system for your department mix and bed count. If your facility also generates industrial-type effluent from labs or diagnostics, our effluent treatment systems for healthcare facilities cover that stream separately.
Sizes equalisation specifically for disinfectant and OT shock loads by default, not as an optional upgrade most suppliers only offer once problems surface.
Addresses pharmaceutical residues through activated carbon or advanced oxidation polishing, targeting compounds standard biological treatment cannot break down.
Builds redundancy into critical components as standard practice, since treatment downtime at a healthcare facility carries different stakes than a commercial building.
Handles batch-style variability from fluctuating patient volume and emergency admissions, sized against realistic peak scenarios rather than average daily flow.
Supports water reuse for flushing, gardening, and cooling needs, reducing freshwater dependency for hospitals operating in water-stressed regions.
Sewage and liquid effluent treatment falls under the Water Act, 1974, and CPCB/SPCB discharge norms, the same framework governing any STP. Solid and infectious biomedical waste, syringes, dressings, and tissue, is governed separately under the Biomedical Waste Management Rules, 2016, requiring disposal through a Common Biomedical Waste Treatment Facility, not an STP. Many facilities conflate these two systems. A hospital needs both working correctly to be genuinely compliant, and we've seen this gap flagged during CPCB inspections more than once.
Disinfectant discharge from cleaning cycles and OT turnover arrives in concentrated bursts rather than a steady stream, and undersized equalisation shows up as inconsistent treatment performance rather than an obvious failure, making it easy to miss until a routine inspection flags it. Trity Environ Solutions sizes equalisation for these shock loads from the outset, drawing on the same engineering discipline behind our broader biological wastewater reactor range, backed by an Annual Maintenance Contract calibrated to healthcare-grade reliability. Talk to our team about AMC coverage for your facility.
Standard biological treatment doesn't remove pharmaceutical residues, so any facility with meaningful antibiotic use or an oncology department needs activated carbon adsorption or advanced oxidation added as a dedicated polishing stage, not offered only as an expensive upsell. We recommend this wherever a facility's department mix genuinely calls for it, based on actual patient load rather than a blanket policy.
Compact biological reactor suited to tight urban plots, the practical choice for clinics and nursing homes generating 1 to 20 KLD.
Batch-cycle technology that handles fluctuating patient volume better than continuous-flow designs, suited to mid-sized hospitals of 20 to 200 KLD.
Membrane based system delivering higher output quality for facilities prioritising treated water reuse, at a higher cost than MBBR or SBR alone.
Activated carbon or advanced oxidation polishing added for facilities with significant oncology or high antibiotic use departments generating pharmaceutical residues.
Physical solids and debris are screened out, and equalisation, sized larger than a standard design, buffers disinfectant and OT shock loads.
MBBR or SBR technology reduces organic load, with SBR preferred where patient volume and discharge patterns fluctuate significantly.
Pathogen removal goes beyond a standard tertiary stage, addressing the elevated bacteria and virus concentrations typical of hospital wastewater.
Activated carbon adsorption or advanced oxidation targets active pharmaceutical ingredients that biological treatment alone cannot remove.
Hospital wastewater carries pharmaceutical residues, disinfectant chemicals, and pathogen loads that standard biological treatment doesn't fully address, making a hospital-specific STP necessary for both compliance and environmental protection.
No, solid and infectious biomedical waste is governed separately under the Biomedical Waste Management Rules, 2016, and disposed of through a Common Biomedical Waste Treatment Facility. An STP treats liquid sewage discharge only.
CPCB and state pollution boards generally require healthcare facilities above a certain bed count to install a functioning STP, though the exact threshold varies by state.
Not universally, but any facility with significant antibiotic use, an oncology department, or other high-pharmaceutical-load departments should include activated carbon or advanced oxidation polishing.
In many cases yes, adding an activated carbon or advanced oxidation polishing stage to an existing plant can significantly improve pharmaceutical residue removal without a full system rebuild.
Small clinics typically need 1 to 20 KLD, mid-sized hospitals 20 to 200 KLD, and larger hospitals with specialised units like oncology can require 50 KLD to 1 MLD or more.
Our engineering team can help design the right system for your capacity, industry, and compliance requirements.